Chenodeoxycholic acid in Cerebrotendinous Xanthomatosis episode artwork

EPISODE · Nov 18, 2025 · 25 MIN

Chenodeoxycholic acid in Cerebrotendinous Xanthomatosis

from JIMD Podcasts · host Journal of Inherited Metabolic Disease

A nationwide CTX study, a critical treatment window, and a conversation with the lead author. Dr Tanyel Zübarioğlu joins the JIMD Podcast to unpack the long-term impact of CDCA therapy and why timing matters more than ever. Long-Term Outcomes of Chenodeoxycholic Acid Therapy for Cerebrotendinous Xanthomatosis: A Nationwide Study on Prognostic Factors and Treatment Tanyel Zubarioglu, et al https://doi.org/10.1002/jimd.70069 Editorial Comment to Regulatory News Carla E. M. Hollak, Natalja Bouwhuis https://doi.org/10.1002/jimd.70071

Episode metadata supplied by the publisher feed · Published Nov 18, 2025

Embed this episode

NOW PLAYING

Chenodeoxycholic acid in Cerebrotendinous Xanthomatosis

0:00 25:22

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of JIMD Podcasts?

This episode is 25 minutes long.

When was this JIMD Podcasts episode published?

This episode was published on November 18, 2025.

Can I download this JIMD Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!